

REMARKS

In view of the preceding amendments and the comments which follow, amendment and reconsideration of the Official Action of September 6, 2002 is respectfully requested by Applicant.

Amendments to specification

The title has been amended pursuant to the Examiner's requirement.

"Clean" and "marked up" versions of page 1 of the specification are attached hereto.

Amendments to claims

Claims 46-53 have been cancelled without prejudice as being drawn to a non-elected invention.

Claims 18, 26, 27, 37 and 38 have been amended to recite that the solution of the invention is characterized by the absence of glucose-6-phosphate dehydrogenase.

"Clean" and "marked up" versions of currently pending claims 18-45 are attached hereto.

Rejection under 35 USC §103 (a)

The Examiner has maintained the rejection of claims 18-45 under 35 USC §103 (a) as being unpatentable over U.S. Patent No. 5,424,204 issued to Aoyama *et al.* (hereinafter "Aoyama"). It is the Examiner's position that, as claimed, the invention is obvious over Aoyama because no degree of stability is claimed that would render Aoyama distinct from the claims. Further, the compositions of Aoyama are described as stable and therefor it would be presumed all the components of the compositions would be stable including the NADH.

In response, Applicant has amended claims 18, 26, 27, 37 and 38 to recite that the stabilized solution of the invention is characterized by the absence of glucose-6-phosphate dehydrogenase. The remaining claims are dependent from claims 18, 26, 27, 37 and 38 and are thereby similarly limited. This distinguishes the claimed invention from that of Aoyama, who teaches a solution requiring the enzyme glucose-6-phosphate dehydrogenase, since the stabilization of glucose-6-phosphate dehydrogenase is the whole purpose of Aoyama's teaching (see, for example, the abstract; column 1, lines 51-56; column 5, lines 38-40; Example 1 and Example 2).

As now amended, Applicant's claims are specifically limited to solutions characterized by the absence of glucose-6-phosphate dehydrogenase and are thus distinct from Aoyama. Thus, Applicant argues that the Examiner has failed to make a *prima facie* case of obviousness, and reconsideration of the rejection of claims 18-45 is respectfully requested.

\* \* \* \* \*

Applicants submit that their application is now in condition for allowance, and favorable reconsideration of their application in light of the above amendments and remarks is respectfully requested. Allowance of claims 18-45 at an early date is earnestly solicited.

The Examiner is hereby authorized to charge any fees associated with this Amendment to Deposit Account No. 02-2958. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: Dec. 4, 2002

Marilyn Amick  
Marilyn L. Amick, Reg. No. 30,444  
Roche Diagnostics Corporation  
9115 Hague Road  
Indianapolis, IN 46250  
Phone: 317-521-7561  
Fax: 317-521-2883



~~Stabilized coenzyme solutions and their use for determining dehydrogenases or substrates thereof~~

TECH CENTER 1600/2900

DEC 1 0 2002

RECEIVED

### STABILIZED COENZYME SOLUTIONS

The invention concerns stabilized aqueous solutions of a coenzyme for hydrogen-transferring enzymes and their use for determining a corresponding analyte (substrate) in a reduced form or for determining the enzyme activity of a corresponding dehydrogenase. The stabilized solution contains an organic compound or appropriate salts having a pKa value between 1.5 and 6.0 and/or a hydroxylamine derivative.


The determination of enzyme activities (or substrate concentrations), especially in blood serum or plasma, plays an important role in clinical chemical diagnostics. Test procedures are often used for this which are based on the reduction of nicotinamide adenine dinucleotide ("NAD") or nicotinamide adenine dinucleotide phosphate ("NADP") and photometric detection of the resulting change of the absorption behaviour in the ultraviolet wavelength range ( $\lambda = 334, 340$  or  $365$  nm). When suitable test conditions have been selected, this change is linearly proportional to the enzyme activity (or substrate concentration) to be determined.

Nowadays the methods described in Eur. J. Clin. Chem. Clin. Biochem. 31, 897 (1994) and Eur. J. Clin. Chem. Clin. Biochem. 32, 639 (1994) are generally recommended for determining the enzyme activity of for example lactate dehydrogenase (LDH, E.C.1.1.1.27). The test

CLAIMS MARKED TO SHOW CHANGES OF 021206

What is claimed is:

18. An aqueous solution comprising a hydrogen-accepting coenzyme selected from the group consisting of NAD, NADP and derivatives thereof and one or more compounds selected from the group consisting of organic compounds or salts thereof having a pKa value between 1.5 and 6.0 and nitrogen compounds of the formula



in which R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are the same or different and denote hydrogen or a saturated or unsaturated alkyl or aryl group, the solution characterized by the absence of glucose-6-phosphate dehydrogenase.

19. The solution of claim 18 wherein the organic compound is citric acid or a citrate salt.
20. The solution of claim 19 wherein the concentration of the citric acid or citrate salt is about 5 to 200 mM.
21. The solution of claim 18 wherein the pH is between 1.0 and 7.0.
22. The solution of claim 18 wherein the nitrogen compound is a hydroxylamine derivative or salt thereof.
23. The solution of claim 22 wherein the concentration of the hydroxylamine derivative or salt is between about 2 and 300 mM.
24. The solution of claim 18 further comprising a boric acid derivative.

RECEIVED


DEC 10 2002

TECH CENTER 1600/2900

25. The solution of claim 24 wherein the concentration of the boric acid derivative is about 50 to 200 mM.

26. A method for determining the concentration of a hydrogen-transferring substrate in a sample comprising:

- (a) forming a reaction mixture by combining the sample with a hydrogen-transferring enzyme for the substrate, a hydrogen-accepting coenzyme selected from the group consisting of NAD, NADP and derivatives thereof, and one or more compounds selected from the group consisting of organic compounds or salts thereof having a pKa value between 1.5 and 6.0 and nitrogen compounds of the formula



in which R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are the same or different and denote hydrogen or a saturated or unsaturated alkyl or aryl group, the reaction mixture characterized by the absence of glucose-6-phosphate dehydrogenase, and


- (b) detecting the change in absorbance of the coenzyme as a measure of the concentration of the substrate present in the sample.

27. A method for determining the activity of a hydrogen-transferring enzyme in a sample comprising:

- (a) forming a reaction mixture by combining the sample with a hydrogen-transferring substrate for the enzyme, a hydrogen-accepting coenzyme selected from the group consisting of NAD, NADP and derivatives thereof, and one or more compounds selected from the group consisting of

## CLAIMS MARKED TO SHOW CHANGES OF 021206

organic compounds or salts thereof having a pKa value between 1.5 and 6.0 and nitrogen compounds of the formula



in which R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are the same or different and denote hydrogen or a saturated or unsaturated alkyl or aryl group, the reaction mixture characterized by the absence of glucose-6-phosphate dehydrogenase, and

- (b) detecting the change in absorbance of the coenzyme as a measure of the activity of the enzyme present in the sample.
28. The method of claim 26 wherein the hydrogen-transferring substrate is selected from the group consisting of lactate, glutamate, ammonia, alcohol, glyceraldehyde-3-phosphate and glucose.
29. The method of claim 27 wherein the enzyme is selected from the group consisting of dehydrogenases of lactate, glutamate, alcohol, glycerol-3-phosphate and glucose.
30. The method of claim 26 or 27 wherein the organic compound is citric acid or a citrate salt.
31. The method of claim 30 wherein the concentration of the citric acid or citrate salt is about 5 to 200 mM.
32. The method of claim 26 or 27 wherein the pH of the reaction mixture is between about 8.5 and 10.0.

33. The method of claim 26 or 27 wherein the nitrogen compound is a hydroxylamine derivative or salt thereof.
34. The method of claim 33 wherein the concentration of the hydroxylamine derivative or salt is between about 2 and 300 mM.
35. The method of claim 26 or 27 wherein the reaction mixture further comprises a boric acid derivative.
36. The method of claim 35 wherein the concentration of the boric acid derivative is about 50 to 200 mM.
37. A kit for determining the concentration of a hydrogen-transferring substrate in a sample comprising:
- (a) a first reagent comprising a hydrogen-transferring enzyme for the substrate in a buffer having a pH between about 8.5 and 10.0 and
  - (b) a second reagent comprising a hydrogen-accepting coenzyme selected from the group consisting of NAD, NADP and derivatives thereof and one or more compounds selected from the group consisting of organic compounds or salts thereof having a pKa value between 1.5 and 6.0 and nitrogen compounds of the formula
$$\text{R}^1\text{—O—N}\begin{matrix} \text{R}^2 \\ \text{R}^3 \end{matrix}$$
in which R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are the same or different and denote hydrogen or a saturated or unsaturated alkyl or aryl group, the second reagent characterized by the absence of glucose-6-phosphate dehydrogenase.



38. A kit for determining the activity of a hydrogen-transferring enzyme in a sample comprising:
- (a) a first reagent comprising a hydrogen-transferring substrate for the enzyme and a buffer having a pH between about 8.5 and 10.0 and
  - (b) a second reagent comprising a hydrogen-accepting coenzyme selected from the group consisting of NAD, NADP and derivatives thereof and one or more compounds selected from the group consisting of organic compounds or salts thereof having a pKa value between 1.5 and 6.0 and nitrogen compounds of the formula
$$\begin{array}{c} \text{R}^2 \\ | \\ \text{R}^1-\text{O}-\text{N} \\ | \\ \text{R}^3 \end{array}$$
in which R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are the same or different and denote hydrogen or a saturated or unsaturated alkyl or aryl group, the second reagent characterized by the absence of glucose-6-phosphate dehydrogenase.
39. The kit of claim 37 or 38 wherein the organic compound is citric acid or a citrate salt.
40. The kit of claim 39 wherein the concentration of the citric acid or citrate salt is about 5 to 200 mM.
41. The kit of claim 37 or 38 wherein the second reagent has a pH between about 1.0 and 7.0.
42. The kit of claim 37 or 38 wherein the nitrogen compound is a hydroxylamine derivative or salt thereof.


## CLAIMS MARKED TO SHOW CHANGES OF 021206

43. The kit of claim 42 wherein the concentration of the hydroxylamine derivative or salt is about 2 to 300 mM.

44. The kit of claim 37 or 38 wherein the first reagent further comprises a boric acid derivative.

45. The kit of claim 44 wherein the concentration of the boric acid derivative is about 50 to 200 mM.

46. ~~A method for stabilizing an aqueous solution comprising a hydrogen-accepting coenzyme selected from the group consisting of NAD, NADP and derivatives thereof, the method comprising adding to the solution one or more compounds selected from the group consisting of organic compounds or salts thereof having a pKa value between 1.5 and 6.0 and nitrogen compounds of the formula~~



~~in which R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are the same or different and denote hydrogen or a saturated or unsaturated alkyl or aryl group.~~

47. ~~The method of claim 46 wherein the organic compound is citric acid or a citrate salt.~~

48. ~~The method of claim 47 wherein the concentration of the citric acid or citrate salt is about 5 to 200 mM.~~

49. ~~The method of claim 46 wherein the pH is between 1.0 and 7.0.~~

CLAIMS MARKED TO SHOW CHANGES OF 021206

50. ~~The method of claim 46 wherein the nitrogen compound is a hydroxylamine derivative or salt thereof.~~

51. ~~The method of claim 50 wherein the concentration of the hydroxylamine derivative or salt is between about 2 and 300 mM.~~

52. ~~The method of claim 46 further comprising a boric acid derivative.~~

53. ~~The method of claim 52 wherein the concentration of the boric acid derivative is about 50 to 200 mM.~~